MIRM News and Press, Mirum Pharmaceuticals Inc. From 07/28/22

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter financial results on Thursday, August 4, 2022. That same day, Mirum will host a conference call to discuss the company’s progress and priorities for 2022. Conference call details: ...

Albireo promotes international sales of its approved product Bylvay for the treatment of the extremely rare and orphan disease PFIC. Investors do not yet appreciate the full potential of Bylvay, which presents a good entry opportunity for investors. Bylvay - a potential product as...

- Six-year natural history comparison with maralixibat demonstrates event-free and transplant-free survival in patients with Alagille syndrome - Maralixibat data highlighting predictors of event-free survival in patients with Alagille syndrome nominated for prestigious Alex Mowat Pr...

Largest multinational survey highlights impact of pruritus on quality of life for patients with primary sclerosing cholangitis Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) presented data at the International Liver Congress™ of The European Association for the Study of t...

- Eight abstracts accepted, including three oral presentations - Maralixibat data highlighting predictors of event-free survival in patients with Alagille syndrome nominated for prestigious Alex Mowat Prize for best oral presentation in hepatology Mirum Pharmaceuticals, Inc....

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Saira Ramasastry to the Company’s board of directors and as a member of the audit committee where she will bring to bear her more than 20 years of financial leadership. “Saira’s extens...

Mirum's maralixibat was approved in September. The company looks like it is executing very well. I am waiting for dips to buy back in. For further details see: Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent

Mirum Pharmaceuticals (NASDAQ:MIRM) has acquired San Diego-based Satiogen Pharmaceuticals. Mirum will wholly own the Satiogen subsidiary, which will receive a 2% royalty. The total potential consideration consisted of a combination of 841,792 shares of common stock, 199,993 of which is subjec...

- Transaction reduces royalty and milestone obligations for LIVMARLI® and volixibat - Cash flow positive transaction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it has acquired Satiogen Pharmaceuticals, Inc., a San Diego-based company. Satiog...

Two new Breakout Stocks for Week 21 with better than 10% short-term upside potential, and two Dow 30 Picks. Average cumulative returns now up to +67.1% YTD. High frequency breakouts continue despite Negative Momentum Gauge® signals, with peak gains in 1 of 4 picks above 10%: SCSC...